After almost a decade of collaboration on OBI-1 (Factor VIII) for hemophilia - working on therapeutics for bleeding disorders - in the Summer 2008, it was announced that Ipsen would buy from Octagen all assets related to the candidate. Over many years, the firm had been working with University of Minnesota entirely organized around developing and commercializing a new generation of recombinant factor VIII products for hemophiliacs and other individuals with clotting disorders. The original IP - second-generation recombinant Factor VIII molecules, in preclinical development, has been licensed from Emory University.
